Helping validated therapeutic innovations reach more patients.

Software & Solutions

SVRN enables medtech and biotech companies to access tailored, non-dilutive financing to power commercialization — enabling innovations to reach patients faster and at greater scale.

Non-Dilutive Financing For Medtech and Biotech.

SVRN's commercial, scientific, and access experts create tailored, non-dilutive capital solutions, so that founders and innovators can access funding for growth while maintaining strategic control.

Funding without equity dilution or loss of IP ownership

Bring life-saving and life-improving products to patients faster

Scale access to innovative therapeutics, diagnostics, and medical devices

Preserve strategic independence while accelerating adoption

Enhanced credibility from deep sector expertise

Unlock the value held in future margins, supported through expert analysis

Partner with commercial, scientific, and access experts

Informed diligence even for therapeutic areas outside the focus of institutional platforms

Company Impact

Purpose-driven capital, with measurable impact.

SVRN originates revenue-based investments into biomedical innovations with high potential for patient impact.

Built on alignment

SVRN investments strategically align innovators and investors, linking patient impact with financial returns:

Returns scale as products are adopted by doctors and patients

Financial performance reflects patient access, not corporate exits

No trade-off between patient impact and investor outcomes

Learn more

“Our tailored, asset-backed financings propel companies through critical inflection points, to help their technologies reach more patients, faster. Structure and timing are customized to meet the needs of each innovator.“

Max Hunt

Investment in patient impact

SVRN's model provides investors exposure to life sciences growth at the nexus of key strategic goals:

Patient benefit

Commercial execution

Financial returns

Explore SVRN's Investors Page

Learn more

The Commercialization Capital Gap

Find answers to the most common questions about our approach. SVRN empowers life sciences companies to access structured, non-dilutive capital through synthetic capped royalty and revenue-based financing.